- Price is above the Trend Line, keeping the weekly tape constructive.
- Latest weekly return ranks in the strongest part of its sector group.
NAN
ASX
Week ended 07 Aug 2026
Weekly Investor Report
Nanosonics Limited · Healthcare · Medical Instruments & Supplies
Latest close
3.57 AUD
13.7%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is 2.6% above the Trend Line and sits at 34.4% of its 52-week range. The latest completed week returned 13.7%, after a 10.2% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 55/100.
Setup score
36
out of 100
Latest Close
3.57 AUD
7 Aug 2026
1W Return
13.7%
latest completed week
4W Return
10.2%
short-term follow-through
12W Return
2.9%
quarterly tape
Trend Breadth
0.0%
0 of 52 weeks active
Volume Ratio
1.1x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
13.7%
Latest completed week; four-week move 10.2%.
Indicator stack
0/44
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
55/100
21 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 2.6% above the Trend Line and sits at 34.4% of its 52-week range. The latest completed week returned 13.7%, after a 10.2% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0412-week average 0.13
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.04Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 10.2% over four weeks, 2.9% over 12 weeks, and -9.8% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.44Latest activity-pressure read.
Pressure change29.1%Four-week change in activity pressure.
Leadership-10.31Latest relative-leadership reading.
RS change34.2%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 30 Jun 2025
Field coverage 82%
Model confidence 42%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength18/100Blend of value, momentum, and quality. Underlying universe rank 83; rank 1 is best.
Value3/100Relative valuation strength. Underlying universe rank 98; rank 1 is best.
Quality96/100Profitability and accounting quality. Underlying universe rank 5; rank 1 is best.
Momentum13/100Medium-term price momentum. Underlying universe rank 88; rank 1 is best.
Growth95/100Revenue and earnings growth. Underlying universe rank 6; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework12/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 51.6x Price divided by trailing earnings.
- Price / sales
- 5.4x Market value relative to trailing revenue.
- EV / EBITDA
- 28.7x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 3.9% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 78.2% Gross profit retained from each unit of revenue.
- Operating margin
- 4.5% Operating profit retained from revenue.
- Free-cash-flow margin
- 17.7% Free cash flow generated from revenue.
- Return on invested capital
- 11.9% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 16.0% Latest one-year revenue growth.
- EPS growth
- 59.1% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 74.0% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -0.0% Net share repurchases relative to market value.
- Shareholder yield
- -0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -4.8x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment55/100
Weighted news tone is neutral across 21 relevant articles.
6 positive · 15 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-25.2%Distance below the 52-week high.
13-week volatility5.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher14 of 2611 weeks finished lower.
Best week+13.7%Week of 7 Aug.
Worst week-9.2%Week of 1 May.
Latest week+13.7%Week of 7 Aug.
Shape of recent returns
Strong gains7
Modest gains7
Flat weeks1
Modest losses5
Sharp losses6
Recent vol5.2%13-week weekly-return volatility.
Base vol4.9%52-week weekly-return volatility.
Up/down split25/26Count of positive and negative weeks in the 52-week window.
Average skew3.9% / -4.0%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorAU Healthcare
4-week rank18 / 100
Group average-0.9%
Trend breadth25.0%
Trend25.0%active weekly trend signals
MD58.0%positive activity pressure
RS26.0%positive relative leadership
Four-week leaders
IndustryAU Medical Instruments & Supplies
4-week rank2 / 7
Group average-2.5%
Trend breadth0.0%
Trend0.0%active weekly trend signals
MD57.1%positive activity pressure
RS28.6%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape29/100
Trend, activity pressure, participation, and risk combine to a 29/100 tape read.
Indicator analysis9/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.04; No reversal markers Factors33/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 65; Small Cap Core rank 99 SVQF12/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 226.5 of 258 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment55/100Weighted news tone is neutral across 21 relevant articles.
Nanosonics Limited Revenue Breakdown – ASX:NAN Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 3.57 AUD | 13.7% | 3.48 AUD | 3.69 AUD | -0.44 | -10.31 | 1.9M | Off |
| 31 Jul 2026 | 3.14 AUD | 5.4% | 3.50 AUD | 3.70 AUD | -0.93 | -18.83 | 1.4M | Off |
| 24 Jul 2026 | 2.98 AUD | -5.4% | 3.52 AUD | 3.71 AUD | -0.84 | -21.51 | 2.1M | Off |
| 17 Jul 2026 | 3.15 AUD | -2.8% | 3.56 AUD | 3.73 AUD | -0.75 | -17.64 | 1.8M | Off |
| 10 Jul 2026 | 3.24 AUD | -3.3% | 3.59 AUD | 3.74 AUD | -0.61 | -15.67 | 1.5M | Off |
| 3 Jul 2026 | 3.35 AUD | 4.0% | 3.61 AUD | 3.75 AUD | -0.52 | -13.53 | 292.2K | Off |
| 26 Jun 2026 | 3.22 AUD | -2.7% | 3.64 AUD | 3.75 AUD | -0.46 | -16.38 | 390.9K | Off |
| 19 Jun 2026 | 3.31 AUD | -0.3% | 3.67 AUD | 3.76 AUD | -0.50 | -15.10 | 524.0K | Off |
| 12 Jun 2026 | 3.32 AUD | 4.4% | 3.70 AUD | 3.77 AUD | -0.45 | -15.01 | 817.6K | Off |
| 5 Jun 2026 | 3.18 AUD | 0.6% | 3.72 AUD | 3.78 AUD | -0.43 | -17.41 | 4.5M | Off |
| 29 May 2026 | 3.16 AUD | -4.0% | 3.75 AUD | 3.79 AUD | -0.47 | -19.40 | 1.0M | Off |
| 22 May 2026 | 3.29 AUD | -5.2% | 3.80 AUD | 3.80 AUD | -0.40 | -15.96 | 4.0M | Off |
| 15 May 2026 | 3.47 AUD | 2.1% | 3.84 AUD | 3.81 AUD | -0.37 | -11.70 | 1.5M | Off |
| 8 May 2026 | 3.40 AUD | 1.2% | 3.88 AUD | 3.82 AUD | -0.47 | -15.22 | 2.2M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.